Bioinspired Honokiol Analogs and Their Evaluation for Activity on the Norepinephrine Transporter

Kristen Stout 1,2, Marketa Bernaskova 3, Gary W. Miller 1,2*, Antje Hufner 3* and Wolfgang Schuehly 4,5

1 Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Claudia Nance Rollins Bldg, Atlanta, GA 30322, USA; kristen.stout@gmail.com (K.S.); gwmille@emory.edu (G.W.M.)
2 Columbia University Mailman School of Public Health, 722 West 168th Street, Room 1411B, New York, NY 10032, USA
3 Institute of Pharmaceutical Sciences, Pharmaceutical Chemistry, Universitätsplatz 1, University of Graz, 8010 Graz, Austria; mbernaskova@centrum.cz (M.B.); antje.huefner@uni-graz.at (A.H.)
4 Institute of Pharmaceutical Sciences, Pharmacognosy, Universitätsplatz 4, University of Graz, 8010 Graz, Austria
5 Institute of Biology, Universitätsplatz 2, University of Graz, 8010 Graz, Austria
* Correspondence: wolfgang.schuehly@uni-graz.at

Received: 4 August 2018; Accepted: 26 September 2018; Published: 4 October 2018

Abstract: In traditional Asian medicinal systems, preparations of the root and stem bark of Magnolia species are widely used to treat anxiety and other nervous disturbances. The biphenyl-type neolignans honokiol and magnolol are the main constituents of Magnolia bark extracts. In the central nervous system, Magnolia bark preparations that contain honokiol are thought to primarily interact with γ-aminobutyric acid A (GABA_A) receptors. However, stress responses inherently involve the noradrenergic system, which has not been investigated in the pharmacological mechanism of honokiol. We present here interactions of honokiol and other synthesized biphenyl-type neolignans and diphenylmethane analogs with the norepinephrine transporter (NET), which is responsible for the synaptic clearance of norepinephrine and the target of many anxiolytics. Of the synthesized compounds, 16 are new chemical entities, which are fully characterized. The 52 compounds tested show mild, non-potent interactions with NET (IC_{50} > 100 µM). It is thus likely that the observed anxiolytic effects of, e.g., Magnolia preparations, are not due to direct interaction with the noradrenergic system.

Keywords: honokiol derivatives; norepinephrine transporter; HEK cell expressing hNET; biphenyl-type neolignans; diphenylmethanes; Magnolia officinalis

1. Introduction

For centuries, traditional Chinese and Japanese medicinal preparations from Magnolia bark have been used to treat neurological diseases, including anxiety and sleep disorders [1]. Study of these preparations led to the identification of the biphenyl neolignans honokiol (H) and magnolol (M) as the major active constituents [2]. While these compounds act promiscuously in the periphery [3], the central nervous system activity of H and M has only been linked to interaction with GABA_A receptors [4].

It is possible that these biphenyl-type neolignans exert pharmacological activity on other CNS targets. In Western medicine, anxiolytic and antidepressant therapeutics (e.g., norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, or tricyclic antidepressants) generally increase noradrenaline levels by inhibiting the norepinephrine transporter (NET) [5]. NET localizes to the presynaptic membrane, where it acts to clear synaptic norepinephrine, thereby terminating
signalling and recycling the neurotransmitter for subsequent release. Given the anxiolytic efficacy of \( H \) and \( M \), we hypothesized biphenyl neolignans may similarly inhibit NET, a question that has not been addressed in the context of active ingredients from Magnolia-containing preparations. In addition to anxiolytic treatment, NET inhibitors are effective in the treatment of depression and attention deficit hyperactive disorder (ADHD). It is also considered a target for therapeutics against neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease [6], and in sleep regulation [7]. Thus, these compounds may offer therapeutic efficacy for a myriad of CNS disturbances.

Biphenyls are considered privileged structures due to their over-proportionally frequent biological activity [8]. In our previous investigations, we focused on the diverse biological activities of \( H \), \( M \), and derivatives thereof, such as COX-1/2, 5-LOX and LTB_4-formation [9], GABA_A receptor activity [10,11], CB_2 receptor activity [12], and toxicity on several cancer cell lines [13]. In this paper, we focus on the activity of the compounds at the NET. We tested 32 compounds of our already existing compound library and 16 additional compounds, of which 14 are new chemical substances (see Tables 1–5). Altogether 52 compounds have been evaluated in a norepinephrine (NE) uptake assay using a human embryonic kidney cell line stably expressing human NET (hNET) and human vesicular monoamine transporter 2 (VMAT2); human VMAT2 (hVMAT2) was added in addition to hNET to more faithfully recapitulate norepinephrine neurons in vitro (see characterization in Figure 1).

**Table 1. Structures of Compounds Based on Honokiol.**

<table>
<thead>
<tr>
<th>Cpd.</th>
<th>( R^1 )</th>
<th>( R^2 )</th>
<th>( R^3 )</th>
<th>( R^4 )</th>
<th>( R^5 )</th>
<th>( R^6 )</th>
</tr>
</thead>
<tbody>
<tr>
<td>( H )</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_1 )</td>
<td>Me</td>
<td>H</td>
<td>NH_2</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_2 )</td>
<td>H</td>
<td>Me</td>
<td>NH-COC_11H_{23}</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_3 )</td>
<td>H</td>
<td>Me</td>
<td>NH-Ala</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_4 )</td>
<td>H</td>
<td>Me</td>
<td>NH-Phe</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_5 )</td>
<td>Et</td>
<td>NH_2</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
<td></td>
</tr>
<tr>
<td>( H_6 )</td>
<td>Et</td>
<td>Me</td>
<td>NH_2</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_7 )</td>
<td>Et</td>
<td>Me</td>
<td>NH-Ac</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_8 )</td>
<td>H</td>
<td>Me</td>
<td>NH-Ac</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_9 )</td>
<td>Me</td>
<td>H</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>NH-Ac</td>
</tr>
<tr>
<td>( H_{10} )</td>
<td>H</td>
<td>Et</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{11} )</td>
<td>H</td>
<td>Me</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{12} )</td>
<td>Me</td>
<td>H</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>NH_2</td>
</tr>
<tr>
<td>( H_{13} )</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>allyl</td>
<td>1-propenyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{14} )</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>( n )-propyl</td>
<td>( n )-propyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{15} )</td>
<td>Me</td>
<td>H</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{16} )</td>
<td>Me</td>
<td>Me</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{17} )</td>
<td>H</td>
<td>Me</td>
<td>H</td>
<td>allyl</td>
<td>1-propenyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{18} )</td>
<td>H</td>
<td>Me</td>
<td>H</td>
<td>2,3-dihydroxypropyl</td>
<td>2,3-dihydroxypropyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{19} )</td>
<td>H</td>
<td>Me</td>
<td>H</td>
<td>( n )-propyl</td>
<td>( n )-propyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{20} )</td>
<td>Me</td>
<td>Me</td>
<td>H</td>
<td>( n )-propyl</td>
<td>( n )-propyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{21} )</td>
<td>Et</td>
<td>H</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{22} )</td>
<td>H</td>
<td>Et</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{23} )</td>
<td>Et</td>
<td>H</td>
<td>H</td>
<td>( n )-propyl</td>
<td>( n )-propyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{24} )</td>
<td>Et</td>
<td>Et</td>
<td>H</td>
<td>( n )-propyl</td>
<td>( n )-propyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{25} )</td>
<td>H</td>
<td>Me</td>
<td>H</td>
<td>2-bromopropyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
<tr>
<td>( H_{26} )</td>
<td>Me</td>
<td>H</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
<td>NO_2</td>
</tr>
<tr>
<td>( H_{27} )</td>
<td>Me</td>
<td>H</td>
<td>H</td>
<td>( n )-propyl</td>
<td>( n )-propyl</td>
<td>NO_2</td>
</tr>
<tr>
<td>( H_{28} )</td>
<td>H</td>
<td>Me</td>
<td>NO_2</td>
<td>allyl</td>
<td>allyl</td>
<td>( H )</td>
</tr>
</tbody>
</table>
Table 1. Cont.

<table>
<thead>
<tr>
<th>Cpd.</th>
<th>R¹</th>
<th>R²</th>
<th>R³</th>
<th>R⁴</th>
<th>R⁵</th>
<th>R⁶</th>
</tr>
</thead>
<tbody>
<tr>
<td>H29</td>
<td>Me</td>
<td>H</td>
<td>H</td>
<td>n-propyl</td>
<td>n-propyl</td>
<td>NH₂</td>
</tr>
<tr>
<td>H30</td>
<td>H</td>
<td>Me</td>
<td>NH₂</td>
<td>n-propyl</td>
<td>n-propyl</td>
<td>H</td>
</tr>
<tr>
<td>H31</td>
<td>Me</td>
<td>H</td>
<td>H</td>
<td>n-propyl</td>
<td>n-propyl</td>
<td>NH-Ac</td>
</tr>
<tr>
<td>H32</td>
<td>H</td>
<td>Me</td>
<td>NH-Ac</td>
<td>n-propyl</td>
<td>n-propyl</td>
<td>H</td>
</tr>
</tbody>
</table>

Table 2. Structures of Compounds Based on Biphenyl-2,2'-diol.

Table 3. Structures of Compounds Based on Biphenyl-4,4'-diol.

Table 4. Structures of Compounds Based on Bis(2-hydroxyphenyl)methane.

* Compounds not tested.
Table 5. Structures of Compounds Based on 2,4′-Dihydroxydiphenylmethane.

<table>
<thead>
<tr>
<th>Cpd.</th>
<th>R¹</th>
<th>R²</th>
<th>R³</th>
<th>R⁴</th>
<th>R⁵</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>C1a*</td>
<td>allyl</td>
<td>allyl</td>
<td>H</td>
<td>H</td>
<td>H</td>
</tr>
<tr>
<td>C2</td>
<td>H</td>
<td>H</td>
<td>allyl</td>
<td>H</td>
<td>allyl</td>
</tr>
<tr>
<td>C3*</td>
<td>H</td>
<td>H</td>
<td>H</td>
<td>allyl</td>
<td>allyl</td>
</tr>
<tr>
<td>C4c</td>
<td>Me</td>
<td>H</td>
<td>allyl</td>
<td>H</td>
<td>allyl</td>
</tr>
<tr>
<td>C4b</td>
<td>H</td>
<td>Me</td>
<td>allyl</td>
<td>H</td>
<td>allyl</td>
</tr>
<tr>
<td>C4a</td>
<td>Me</td>
<td>Me</td>
<td>allyl</td>
<td>H</td>
<td>allyl</td>
</tr>
</tbody>
</table>

* Compounds not tested.

A. Plate-reader based fluorescent screening

C. Visualization with high-content imaging

B. Validation by radioactive 3H-DA uptake

Figure 1. Plate reader-based fluorescent assay using human NET in a validation assay of the screening strategy using the known NET inhibitor desipramine as a positive control. Compound screening workflow: (A) All compounds were screened for fluorescent uptake in human embryonic kidney HEK-hNET-hVMAT2 cells (blue hNET, red VMAT2) using a dye that is a substrate for NET, as indicated by inhibition by addition of a selective NET inhibitor, desipramine. (B) Next, fluorescent counts were confirmed with a radiolabelled uptake of dopamine, which is also a substrate of NET, as demonstrated by the lack of uptake in the presence of desipramine. (C) Finally, uptake was visualized using high content imaging with the Array Scan VTI HCS (Cellomics, Thermo Fisher Scientific, Waltham, MA, USA) to visualize nuclei (stained with DAPI), VMAT2-mCherry, and dye. All experiments were conducted in triplicate and analyzed with nonlinear regression analysis in GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Scale: 10 nm.
2. Results and Discussion

Previous studies indicated a significant increase in pharmacological activity when nitrogen-containing functional groups were introduced into compounds [10]. We enhanced our existing compound library with further nitrogen-bearing honokiol derivatives with significantly changed polarity, either by N-acylation of 3-amino-4′-O-methylhonokiol (H1) with a long chain fatty acid (H2) or an amino acid (H3, H4), by formally replacing the methoxy group of H1 with an ethoxy group (H5), or di-O-alkylation without or with N-acetylation (H6, H7). In contrast to amid H8 of our parent library, in H9 acetamido and O-methyl groups are located at C-5′ and C-2, respectively. In the course of the syntheses, intermediates were fully characterized by their chemical and physical properties, but not tested in the biological assay. Compound data is provided for all synthesized chemicals, including compounds mentioned in the literature for which chemical and physical data were not fully provided.

All synthesized compounds were tested for pharmacological activity at the NET and compared with selective NET inhibitor, desipramine (Figure 1). Compounds with any apparent pharmacological activity were further characterized by radioactive uptake and high content imaging. No compound showed robust NET activity (Table 1).

As outlined in Scheme 1, N-acylations of H1 were performed using the corresponding carboxylic acid chlorides [14,15]. An Fmoc-protection group was used for the preparation of the peptide-type amides H3 and H4 [16,17] (see Scheme 1). N-acylation of H6 resulted in H7 (see Scheme 2).

![Scheme 1. Synthesis of honokiol derivatives. Reagents and conditions: i) n-C_{11}H_{23}COCl, pyridine; ii) Fmoc-Ala-Cl, Zn, THF; iii) Fmoc-Phe-Cl, Zn, THF; iv) piperidine.](image)

As outlined in Scheme 2, H5 was prepared analogously to H1 from 4′-O-ethylhonokiol (H10) via nitration with nitric acid followed by reduction with SnCl₂ × 2H₂O [10,18,19]. To avoid N-alkylation in the synthesis of di-O-alkylated amine H6, the O-alkylation of the hydroxy group of 4′-O-methylhonokiol honokiol (H11) had to be performed after nitration and prior to reduction with SnCl₂ × 2 H₂O. N-acetylation of H6 with acetic anhydride resulted in H7 [10]. H9 was prepared by a similar N-acetylation of the corresponding amine H12.
To go one step further, we tested several dioxygenated diphenylmethanes to see if insertion of a methylene group between the two aromatic moieties affects biological activity. As outlined in Scheme 3, the synthesis started from bis(2-hydroxyphenyl)methane (B1) and 2,4′-dihydroxydiphenylmethane (B1), which are commercially available but were also prepared from salicylic alcohol and phenol [20]. Double O-allylation and Claisen rearrangement according to Chattopadhyay et al. [21] yielded mainly the ortho rearrangement products (B2 and C2 resp.) together with little of the para rearrangement products (B3 and C3 resp.). B2 and C2 were submitted to incomplete O-methylation to yield the monoethers B4a, C4b, and C4c together with the respective diether B4a or C4a.

**Scheme 2.** Synthesis of honokiol derivatives. Reagents and conditions: i) HNO₃ (65%), AcOEt; ii) SnCl₂ × 2 H₂O, EtOH; iii) MW irradiation. 1. KOH, 2. MeSO₄ or Et₂SO₄; iv) Ac₂O, H₂O.

**Scheme 3.** Synthesis of diphenylmethane derivatives. Reagents and conditions: i) K₂CO₃, CH₂=CH-CH₂-Br, acetone; ii) Δ, Ph-NMe₂; iii) 1. KOH, 2. Me₂SO₄.
3. Experimental

3.1. General

Microwave reactions were carried out on a CEM Corp. Discover laboratory microwave equipped with an Explorer unit (CEM Corp., Matthews, NC, USA). Infrared spectra were recorded on a Bruker Alpha Platinum ATR spectrometer (Bruker, Kennewick, WA, USA) or as KBr pellets on a Perkin-Elmer 281 B spectrometer (PerkinElmer, Waltham, MA, USA). $^1$H and $^{13}$C-NMR spectra were recorded on a Varian 400 MHz UnityINOVA spectrometer (400 and 100 MHz, respectively, Varian, Palo Alto, CA, USA) and unless otherwise stated in CDCl$_3$ with undeuterated solvent as an internal standard (7.26 ppm and 77.0 ppm, respectively). For convenience, atoms were numbered according to structures in Tables 1, 4 and 5 with double-primed numbers for substituents at ring A and triple primed numbers for substituents at ring B, respectively. ESI-MS were recorded in ESI positive and negative mode on an LC Ultimate 3000 (Thermo, San José, CA, USA) with DAD detection in line with a Thermo Scientific LTQ XL mass spectrometer. Column: Knauer (Berlin, Germany) RP-18 (1.8 µm; 125 × 2.1 mm) with a guard cartridge at a flowrate of 150 µL/min. ESI-MS were recorded on an Agilent Technologies HP 7890A instrument fitted with detector HP 5975C VL MSD (70 eV, ion source 250 °C, quadrupole temperature 150 °C, Santa Clara, CA, USA). An Agilent HP-5MS column (30 m, ID 0.25 mm, film 5% phenyl; 95%, methylpolysiloxane 0.25 µm) was used. The oven temperature was kept at 45 °C for 2 min and programmed to increase to 300 °C at a rate of 3 °C/min, then kept constant at 300 °C for 20 min, with a total run time of 64.5 min. Helium was used as a carrier gas. The injection volume was 1 µL (≈0.5% solution) and a split ratio of 1:50.

For high resolution mass spectrometry, a Waters GCT Premier instrument was used with electron impact ionization (70 eV) at an ion source temperature of 200 °C.

General Information on Syntheses

Compounds were synthesized as described below. Solvents were of analytical quality, if not stated otherwise. The purity of all synthesized compounds was verified using NMR and analytical HPLC. Analytical thin layer chromatography (TLC) was performed using aluminium foil coated with silica 60 F$_{254}$ (Merck, Darmstadt, Germany). Preparative thin layer chromatography (PTLC) was performed using glass plates coated with silica 60 F$_{254}$ (Merck). Detection was done using UV/254 nm and spraying with molybdophosphoric acid and subsequent heating. Compound mixtures were separated using column chromatography (CC) on silica gel 60 (63–200 µm, Merck) using cyclohexane/ethyl acetate mixtures. Further purification was performed using preparative HPLC (Varian Prepsstar with a Dynamax Rainin detector; column SepServ, Berlin, Germany, 250 × 21 mm, RP-18, 7 µm, flow rate 15 mL). Honokiol (purity > 98%) was purchased from APIChem Technology Co. (Hangzhou, China). Proton NMR spectra of the newly described compounds are given under “Supplementary Materials”.

3-Dodecanoylamino-4′-O-methylhonokiol (H2)

Dodecanoyl chloride (0.34 mmol, 80 µL) was added with intense stirring at room temperature (RT) to a solution of 100 mg (0.34 mmol) of H1 and pyridine (0.41 mmol, 33 µL) in abs. Et$_2$O (4 mL). The reaction mixture was stirred at room temperature overnight and filtered. The precipitate was extracted with Et$_2$O (4 mL). NaHCO$_3$ (1 M, 10 mL) was added to the combined filtrate and washings. The organic phase was separated, and the aqueous phase was extracted with Et$_2$O (3 × 10 mL). The combined organic phases were washed with brine (10 mL), dried over Na$_2$SO$_4$, concentrated under reduced pressure, and purified using CC (silica, cyclohexane/ACOEt 5:1) resulting in 107 mg (59%) of a light brown solid (H2).

Compound H2: IR (ATR, ν$_{max}$, cm$^{-1}$): 3304, 2956, 2919, 2847, 2485, 1639, 1606, 1539, 1499, 1467, 1411, 1243, 906, 725, 577; $^1$H-NMR (CDCl$_3$) δ 7.57 (bs, 1H, NH), 7.40 (d, J = 1.5 Hz, 1H, H-4), 7.34 (dd, J = 8.4, 2.3 Hz, 1H, H-6′), 7.27 (d, J = 2.1 Hz, 1H, H-2′), 7.17 (s, 1H, OH), 6.94 (d, J = 8.4 Hz, 1H, H-5′), 6.89 (d, J = 1.9 Hz, 1H, H-6), 6.01 (ddt, J = 16.8, 10.2, 6.6 Hz, 1H, H-2″′), 5.96 (ddt, J = 16.8, 10.0,
6.7 Hz, 1H, H-2′′′), 5.02–5.13 (m, 4H, H-3′′′, H-3′′), 3.87 (s, 3H, OCH3), 3.43 (d, J = 6.6 Hz, 2H, H-1′′′), 3.33 (d, J = 6.7 Hz, 2H, H-1′′), 2.42 (t, J = 7.5 Hz, 2H, Acyl-Hδ), 1.74 (quint, J = 7.3 Hz, 2H, Acyl-Hβ), 1.21–1.42 (m, 16H, Acyl-Hγ), 0.88 (t, J = 6.8 Hz, 3H, Acyl-Hω).13C-NMR (CDCl3) δ 172.7 (CO), 156.8 (C-4′′′), 142.3 (C-2′′), 137.5 (C-2′′′), 136.7 (C-2′′′), 132.2 (C-5), 130.7 (C-2′), 130.7 (C-1), 129.6 (C-1′), 129.0 (C-3′′), 128.1 (C-6′′), 126.7 (C-6), 126.2 (C-3′), 120.3 (C-4′), 115.8 (C-3′′′), 115.6 (C-3′′), 110.5 (C-5′′), 55.5 (OCH3), 39.5 (C-1′′), 37.5 (Acyl-Cα), 34.3 (C-1′′′), 31.9 (Acyl-Cω-2), 2 × 29.6, 29.4, 2 × 29.3, 29.2 (Acyl-Cω-2, Cω-3). 25.7 (Acyl-Cβ), 22.7 (Acyl-Cω-1), 14.1 (Acyl-Cω), ESI+ calc'd for C31H35NO3: [M]+ 477.324; found ESI-MS m/z (rel. int.): 478.63 [M + H]+ (100). From the same batch, the compound has been tested in parallel towards CB1/CB2 receptor agonistic activity by Bertini et al. [22]; however, spectroscopic data and synthesis are only given here.

3-(N-L-Alanyl)-4′-O-methylhonokiol (H3)

L-N-(9-Fluorenylmethoxycarbonyl)alanin chloride, Fmoc-L-Ala-Cl: Fmoc-L-Ala-OH · H2O was first dehydrated at 50 °C over P2O5 in vacuo for 12 h. Under dry conditions 400 mg (1.28 mmol) L-N-(9-Fluorenylmethoxycarbonylation)alanin was suspended in 5 mL dichloromethane, thionyl chloride (freshly distilled, 1.23 mL, 17.7 mmol) was added, and the mixture was sonicated at RT. After 7 min, the reaction mixture was evaporated under reduced pressure and dichloromethane (5 mL) was added. The residue (377 mg) was purified using CC (silica, dichloromethane/MeOH, 1:1) to yield 220 mg (88%) of Fmoc-L-Ala-Cl as a grey solid, which was used without further purification for a second step.

L-3-(N-(9-Fluorenylmethoxycarbonyl)alanyl)-4′-O-methylhonokiol (H3a): Zn (dust) was treated with HCl (2 M, aqueous solution), washed subsequently with water, EtOH and diethylether, dried in vacuo, and stored under argon. Under argon, H1 (259 mg, 0.841 mmol, Fmoc-L-Ala-Cl (279 mg, 0.846 mmol), and Zn dust (55 mg, 0.841 mmol) were suspended in abs. THF (50 mL) and stirred at RT overnight. Over a period of two hours, the reaction color turned from brownish to yellowish. Reaction completion was proven using TLC analysis (cyclohexane/AcOEt = 5:3). Zn dust was filtered off and the filtrate was evaporated in vacuo. The residue was dissolved in dichloromethane (15 mL), washed with brine (2 × 5 mL), and dried over Na2SO4. Evaporation of the solvent in vacuo and CC (silica, cyclohexane/AcOEt = 5:1) yielded H3a (428 mg; 87%).

3-(N-L-Alanyl)-4′-O-methylhonokiol (H3): H3a (401 mg, 0.682 mmol) was dissolved in diethyl ether (3 mL) and piperydine (1 mL, 1 mmol) was added. The mixture was stirred at RT for 1 h. The reaction mixture was evaporated under reduced pressure and dichloromethane (5 mL) was added to the residue. The resulting precipitate was filtered off and the filtrate was concentrated under reduced pressure to dryness. The residue (377 mg) was purified using CC (silica, dichloromethane/MEOH, gradient: 0–10% v/v methanol) to yield 220 mg (88%) of H3 as an orange oil.

Compound H3: IR (ATR, νmax, cm−1): 3272, 3075, 2974, 2929, 2834, 1638, 1606, 1590, 1530, 1500, 1460, 1440, 1244, 1029, 993, 910, 813, 594; 1H-NMR (CDCl3 + D2O) δ 7.35 (dd, J = 8.1, 1.8 Hz, 1H, H-6′), 7.29 (d, J = 2.2 Hz, 1H, H-2′), 7.18 (s, 1H, H-4′), 6.92 (s, 1H, H-6′′), 6.91 (d, J = 8.4 Hz, 1H, H-5′′′), 6.01 (ddt, J = 16.8, 9.8, 6.6 Hz, 1H, H-2′′′′), 5.95 (dddt, J = 16.9, 9.9, 6.6 Hz, 1H, H-2′′′′′), 5.01–5.13 (m, 4H, H-3′′′, H-3′′′′), 3.85 (s, 3H, O–CH3), 3.73 (q, J = 6.2 Hz, 1H, CH3CH(NH2)CO).3.42 (d, J = 6.6 Hz, 2H, H-1′′′′′), 3.32 (d, J = 6.2 Hz, 2H, H-1′′′′′), 2.03 (s, 2H, NH2), 1.45 (d, J = 6.6 Hz, 3H, CH3CH(NH2)CO); 13C-NMR (CDCl3 + D2O) δ 174.6 (CO), 156.7 (C-4′′′), 143.2 (C-2′′′), 137.5 (C-2′′′′), 136.8 (C-2′′′′′), 131.9 (C-5′′′), 131.0 (C-1′′′), 130.8 (C-2′′), 128.6 (C-3′′′), 128.2 (C-6′′′), 127.5 (C-5′), 126.5 (C-3′), 126.0 (C-4′), 115.7 (C-3′′′), 115.5 (C-3′′′′), 110.3 (C-5′′′′), 55.5 (O–CH3), 50.5 (CH3CH(NH2)CO), 39.4 (C-1′′′′′), 34.3 (C-1′′′′′), 21.1 (CH3CH(NH2)CO); ESI+ calc’d for C22H26N2O2: [M]+ 366.194; found ESI-MS m/z (rel. int.): 367.18 [M + H]+ (100).

3-(N-L-Phenylalanyl)-4′-O-methylhonokiol (H4)

L-N-(9-Fluorenylmethoxycarbonyl)phenylalanin chloride, Fmoc-L-Phe-Cl: Under dry conditions 300 mg (0.774 mmol) L-N-(9-Fluorenylmethoxycarbonyl)phenylalanin was suspended in dry dichloromethane (4 mL), thionyl chloride (freshly distilled, 0.776 mL, 10.7 mmol) was added, and the
mixture was sonicated at RT for 45 min. The sonication bath was heated up to 40 °C over that period of time. Dichloromethane and the excess of thionyl chloride were removed in vacuo to yield 294 mg (94%) of Fmoc-l-Phe-Cl as a grey solid, which was used without further purification in the next step.

3-(N-l-Phenylalanyl)-4′-O-methylhonokiol (H4): Zn dust was treated with aqueous HCl (2 M), washed subsequently with water, ethanol, and diethyl ether, dried in vacuo, and stored under argon. Under argon, H1 (75 mg, 0.25 mmol), Fmoc-l-Phe-Cl (103 mg, 0.254 mmol), and Zn dust (17 mg, 0.25 mmol) were suspended in dry THF (10 mL) and stirred for 4 h. Reaction completion was proven using TLC analysis (cyclohexane/AcOEt = 5:3). Piperidine (0.5 mL, 5 mmol) was added and the reaction mixture was stirred for 20 min at RT, the solvent was evaporated under reduced pressure and the residue was diluted with dichloromethane (5 mL), filtered, and evaporated under reduced pressure. The residue (170 mg) was purified using CC (silica, cyclohexane/AcOEt, gradient: 0–100% v/v AcOEt) to yield 50 mg (45%) of H4 as an orange oil.

Compound H4: IR (ATR, v_{\text{max}}, \text{cm}^{-1}): 3270, 3073, 2974, 2834, 1638, 1605, 1530, 1500, 1453, 1439 s, 1244, 1028, 910; 1H-NMR (CDCl$_3$) δ 9.69 (bs, 1H, CONH), 7.39 (dd, J = 8.4, ≈2 Hz, 1H, H-6′), 7.30–7.36 (m, 3H, Ph-H$_{\text{meta}}$ Ph-H$_{\text{para}}$), 7.22–7.30 (m, 3H, H-2′, Ph-H$_{\text{ortho}}$), 7.10 (s, 1H, H-4), 6.95 (s, 1H, H-6), 6.92 (d, J = 8.4 Hz, 1H, H-5′), 6.01 (ddt, J = 16.9, 9.9, 6.6 Hz, 1H, H-2″), 5.97 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, H-2′′), 5.02–5.14 (m, 4H, H-3′, H-3″, H-3′′), 3.86 (s, 3H, OCH$_3$), 3.82 (m, 1H, PhCH$_2$CH(2NH$_2$)CO), 3.43 (d, J = 6.6 Hz, 2H, H-1′′′), 3.34 (m, 1H, PhCH$_2$CH(NH$_2$)CO), 3.33 (d, J = 6.9 Hz, 2H, H-1″), 2.84 (dd, J = 13.6, 9.2 Hz, 1H, PhCH$_2$CH$_2$(NH$_2$)CO) 13C-NMR (CDCl$_3$) δ 173.7 (CO), 156.6 (C-4″′), 143.5 (C-2″), 139.1 (Ph-C$_{\text{ipso}}$), 137.5 (C-2″″), 136.8 (C-2″″′), 131.8 (C-5), 131.2 (C-1), 130.8 (C-2′), 130.2 (C-1′), 129.3 (Ph-C$_{\text{ortho}}$), 128.8 (Ph-C$_{\text{meta}}$), 128.6 (C-3″), 128.2 (C-6″), 127.6 (C-6), 127.0 (Ph-C$_{\text{para}}$), 125.7 (C-3), 120.5 (C-4), 115.7 (C-3″″), 115.5 (C-3″′), 110.3 (C-5′), 56.3 (PhCH$_2$CH(NH$_2$)CO), 55.0 (OCH$_3$), 40.5 (PhCH$_2$CH(NH$_2$)CO), 39.3 (C-1″), 34.3 (C-1″″), ESI$^+$ calculating for C$_{28}$H$_{30}$N$_2$O$_2$: [M]$^+$ 442.226; found ESI-MS m/z (rel. int.): 442.20 [M + H]$^+$ (100).

3-Amino-4′-O-ethylhonokiol (H5)

4′-O-Ethyl-3-nitro-honokiol (H5a): Aqueous nitric acid (65%, 0.474 mL, 6.79 mmol) was added under intense stirring within ≈5 s to a solution of H10 (200 mg, 0.679 mmol; synthesis see Schuehly et al. [12] supplemental; cpd 16b) in AcOEt (5 mL) at RT. The reaction mixture was stirred for 60 s and quenched with NaHCO$_3$ (1 M, 10 mL). The organic phase was separated, and the aqueous phase was extracted with AcOEt (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over Na$_2$SO$_4$, concentrated under reduced pressure, and purified using CC (silica, cyclohexane/AcOEt 99:1) to yield 120 mg (50%) of 4′-O-ethyl-3-nitro-honokiol (H5a) as a dark yellow oil.

Compound H5a: IR (ATR, v_{\text{max}}, \text{cm}^{-1}): 3177, 3078, 2978, 2903, 1638, 1607, 1537, 1502, 1314, 1244, 1045, 912, 672, 555 cm$^{-1}$; 1H-NMR (CDCl$_3$) δ 11.03 (s, 1H, OH), 7.90 (d, J = 2.2 Hz, 1H, H-4), 7.45 (d, J = 2.2 Hz, 1H, H-6), 7.38 (dd, J = 8.4, 2.2, 1H, H-6′), 7.33 (d, J = 2.2 Hz, 1H, H-2′), 6.92 (d, J = 8.4 Hz, 1H, H-5′), 6.03 (ddt, J = 16.9, 10.3, 6.6 Hz, 1H, H-2″), 5.96 (ddt, J = 16.5, 10.3, 6.6 Hz, 1H, H-2″′), 5.03–5.17 (m, 4H, H-3″″ and H-3″″′), 4.10 (q, J = 7.2 Hz, 2H, OCH$_2$CH$_3$), 3.45 (d, J = 6.4 Hz, 2H, H-1″″′), 3.40 (d, J = 6.6 Hz, 2H, H-1″″), 1.46 (t, J = 6.9 Hz, 3H, OCH$_2$CH$_3$), 13C-NMR (CDCl$_3$) δ 156.6 (C-4″′), 151.3 (C-2″), 138.9 (C-6′), 136.8 (C-2″″), 136.0 (C-2″″′), 133.8 (C-3), 132.9 (C-1), 131.7 (C-5), 130.7 (C-2″′), 128.5 (C-3″), 128.2 (C-2″″), 127.4 (C-1″″′), 122.8 (C-4), 117.1 (C-3″″″), 115.6 (C-3″″′), 111.0 (C-5′), 63.7 (OCH$_2$CH$_3$), 38.9 (C-1″″″), 34.5 (C-1″″′), 14.9 (OCH$_2$CH$_3$); ESI$^+$ calculating for C$_{28}$H$_{31}$NO$_4$: [M]$^+$ −339.147; found ESI-MS m/z (rel. int.): 338.21 [M − H$^-$] (100).

3-Amino-4′-O-ethylhonokiol (H5): SnCl$_2$×2H$_2$O (1.62 g, 7.16 mmol) was added to a solution of H5a (270 mg, 0.796 mmol) in abs. MeOH (10 mL). The reaction mixture was stirred for 48 h at RT, concentrated under reduced pressure and diluted with AcOEt (15 mL). The spumy precipitate resulting from the addition of aqueous NaHCO$_3$ (1 M, 20 mL) was filtered off with Celite$^\text{®}$ (Sigma-Aldrich, Buchs, Switzerland) and rinsed with AcOEt (30 mL). The organic layer was separated from the combined filtrate and washings, dried over Na$_2$SO$_4$, and concentrated under reduced pressure. The residue (127 mg) was purified using PTLC (silica, cyclohexane/AcOEt = 5:1) to yield 65 mg (26%) of H5 as a brown oil.
Compound H5: IR (ATR, \(v_{\max}, \text{cm}^{-1}\)): 3544, 3370, 3075, 2977, 2900, 1637, 1607, 1503, 1486,1474, 1242, 1215, 1122, 1044, 908, 808; \(^1\)H-NMR (CDCl\(_3\)) \(\delta\) 7.26 (d, \(J = 9\) Hz, 1H, H-6'), 7.25 (s, 1H, H-2'), 6.93 (d, \(J = 8.1\) Hz, 1H, H-5'), 6.61 (s, 1H, H-4), 6.51 (s, 1H, H-6), 6.00 (ddt, \(J = 16.9, 9.9, 6.6\) Hz, 1H, H-2'''), 5.96 (ddt, \(J = 17.0, 9.9, 6.9\) Hz, 1H, H-2'), 5.02–5.14 (m, 4H, H-3''', H-3'''), 4.19 (bs, 2H, NH\(_2\)), 4.09 (q, \(J = 7.0\) Hz, 2H, OCH\(_2\)CH\(_3\)), 3.43 (d, \(J = 6.6\) Hz, 2H, H-1'''), 3.28 (d, \(J = 6.9\) Hz, 2H, H-1''), 1.46 (t, \(J = 7.0\) Hz, 3H, OCH\(_2\)CH\(_3\)); \(^{13}\)C-NMR (CDCl\(_3\)) \(\delta\) 156.4 (C-4), 139.0 (C-2), 137.9 (C-2'''), 136.6 (C-2'''), 133.6 (C-3), 132.4 (C-5), 130.3 (C-3), 129.9 (C-1'), 127.9 (C-1), 127.7 (C-6'), 120.5 (C-6), 115.8 (C-3'''), 115.7 (C-4), 115.4 (C-3'''), 111.9 (C-5'), 63.7 (OCH\(_2\)CH\(_3\)), 39.6 (C-1''), 34.5 (C-1'''), 14.9 (OCH\(_2\)CH\(_3\)); ESI\(^+\) calc C\(_{20}\)H\(_{25}\)NO\(_2\): [M]+ 309.173; found ESI-MS m/z (rel. int.): 310.11 [M + H]\(^+\) (100).

3-Amino-2-O-ethyl-4'-O-methylhonokiol (H6)

In a microwave process vial, KOH (132 mg, 2.36 mmol) was added to a solution of 4'-O-ethyl-3-nitro-honokiol (synthesis see [10]) (192 mg, 0.590 mmol) in abs. MeOH (2 mL) and the mixture was stirred at RT for 10 min. Diethyl sulfate (155 µL, 2.36 mmol) was added and the reaction mixture was irradiated in a microwave oven at 90 °C for 60 min. After cooling to RT, the reaction mixture was neutralized with aqueous HCl (2 M). MeOH was evaporated under reduced pressure (40 °C, 100 mbar). The residue was extracted with dichloromethane (3 × 2 mL), the organic phase was washed with water (3 × 5 mL), dried over Na\(_2\)SO\(_4\), and concentrated under reduced pressure, resulting in 198 mg of crude 2-O-ethyl-4'-O-methyl-3-nitro-honokiol, which was used without further purification.

SnCl\(_2\)+2H\(_2\)O (1.09 g, 4.84 mmol) was added to a solution of crude 2-O-ethyl-4'-O-methyl-3-nitro-honokiol (190 mg, 0.54 mmol) in abs. EtOH (10 mL). The reaction mixture was stirred at RT for 48 h. The spumy precipitate resulting from the addition of aqueous NaHCO\(_3\) (1 M, 20 mL) was filtered using Celite\(^\circledast\), the residue was extracted with EtOH (50 mL). Combined organic layers were evaporated under reduced pressure (100 mbar). The residue was extracted with dichloromethane (3 × 10 mL), which was washed with brine (3 × 5 mL), dried over Na\(_2\)SO\(_4\), and concentrated under reduced pressure to yield 107 mg of a crude product, which after purification using PTLC (silica, cyclohexane/AcOEt = 5:1), yielded 26 mg (14%) of H6.

Compound H6: IR (ATR, \(v_{\max}, \text{cm}^{-1}\)): 3417, 3310, 3076, 2975, 2928, 2836, 1674, 1638, 1607, 1522, 1502, 1435, 1245, 1026, 910, 812, 600, 523; \(^1\)H-NMR (CDCl\(_3\)) \(\delta\) 7.47 (d, \(J = 2.2\) Hz, 1H, H-2'), 7.46 (dd, \(J = 8.1, 2.2\) Hz, 1H, H-6'), 6.92 (d, \(J = 8.4\) Hz, 1H, H-5'), 6.60 (s, 2H, H-4, H-6), 6.07 (ddt, \(J = 16.6, 10.2, 6.2\) Hz, 1H, H-2'''), 6.00 (ddt, \(J = 16.9, 9.9, 6.9\) Hz, 1H, H-2''), 5.04–5.17 (m, 4H, H-3''', H-3'''), 3.96 (bs, 2H, NH\(_2\)), 3.89 (s, 3H, OCH\(_3\)), 3.57 (q, \(J = 6.9\) Hz, 2H, OCH\(_2\)CH\(_3\)), 3.46 (d, \(J = 6.6\) Hz, 2H, H-1'''), 3.33 (d, \(J = 6.9\) Hz, 2H, H-1''), 1.16 (t, \(J = 7.1\) Hz, 3H, OCH\(_2\)CH\(_3\)); \(^{13}\)C-NMR (CDCl\(_3\)) \(\delta\) 156.4 (C-4), 142.1 (C-2), 140.0 (C-3), 137.6 (C-2''), 137.0 (C-2'''), 136.0 (C-5), 134.4 (C-1), 131.0 (C-1''), 130.5 (C-2'), 128.0 (C-3'), 127.6 (C-6'), 120.5 (C-6), 115.5 (C-3''), 115.2 (C-3''), 114.7 (C-4), 109.9 (C-5'), 67.6 (C-OCH\(_2\)CH\(_3\)), 55.4 (OCH\(_3\)), 39.9 (C-1''), 34.3 (C-1'''), 15.7 (OCH\(_2\)CH\(_3\)); ESI\(^+\) calc for C\(_{21}\)H\(_{25}\)NO\(_2\): [M]+ 323.189; found ESI-MS m/z (rel. int.): 324.23 [M + H]\(^+\) (100).

3-Acetylamo-2-O-ethyl-4'-O-methylhonokiol (H7)

In a 10 mL round-bottom flask, H6 (34 mg, 0.105 mmol) was mixed with water (0.3 mL), and acetic anhydride (0.21 mmol, 20 µL) was added. The flask was rotated at 80 °C for about 10 min in a water bath. After cooling to RT, the reaction mixture was quenched with aqueous NaHCO\(_3\) (1 M, 2 mL) and extracted with dichloromethane (3 × 2 mL). The combined extracts were washed with aqueous NaHCO\(_3\) (1 M, 2 mL), water (2 mL), dried over Na\(_2\)SO\(_4\), and concentrated under reduced pressure. The crude product (27 mg) was purified using PTLC (cyclohexane/AcOEt = 5:3), yielding 21 mg (55%) of H7 as a brownish oil.

Compound H7: IR (ATR, \(v_{\max}, \text{cm}^{-1}\)): 3469, 3368, 3075, 2974, 2928, 2903, 2834, 1638, 1606, 1504, 1438, 1243, 1209, 1030, 909, 810, 596; \(^1\)H-NMR (CDCl\(_3\)) \(\delta\) 8.17 (s, 1H, H-4), 7.96 (bs, 1H, NH), 7.38 (s, 1H, H-2'), 7.37 (dd, \(J = 8, 2.2\) Hz, 1H, H-6'), 6.90 (d, \(J = 8.1\) Hz, 1H, H-5'), 6.86 (d, \(J = 1.1\) Hz, 1H, H-6),
6.03 (ddt, J = 16.8, 9.9, 6.9 Hz, 1H, H-2′′′), 5.98 (ddt, J = 16.9, 9.9, 6.6 Hz, 1H, H-2′′′), 5.02-5.15 (m, 4H, H-3′′′, H-3′), 3.87 (s, 3H, OCH₃), 3.52 (q, J = 7.1 Hz, 2H, OCH₂CH₃), 3.42 (d, J = 6.6 Hz, 2H, H-1′′′), 3.38 (d, J = 7.0 Hz, 2H, H-1′′′), 2.21 (s, 3H, CH₃CO), 1.14 (t, J = 7.0 Hz, 3H, OCH₂CH₃); ¹³C-NMR (CDCl₃) δ 168.09 (CO), 156.7 (C-4′), 143.1 (C-2), 137.3 (C-2′′′), 136.9 (C-2′′′), 136.2 (C-5), 133.5 (C-1), 131.9 (C-3), 130.4 (C-1′), 130.3 (C-2′), 128.4 (C-3′), 127.6 (C-6′), 125.3 (C-6), 118.7 (C-4), 115.8 (C-3′′′), 115.4 (C-3′′′), 110.2 (C-5′), 68.7 (O-CH₂-CH₃), 55.4 (OCH₃), 40.0 (C-1′), 34.3 (C-1′′′), 24.9 (CH₂-CH₂=O), 15.6 (OCH₂CH₃); ESI⁺ calc'd for C₂₃H₂₇NO₃: [M]+ 365.199; found ESI-MS m/z (rel. int.): 366.29 [M + H]⁺ (100).

5′-(N-Acetylaminio)-2-O-methyl-honokiol (H9)

In a 10 mL round-bottom flask, H12 (for synthesis, see Reference [11]) (37 mg, 0.125 mmol) was suspended with water (1 mL), and acetic anhydride (0.21 mmol, 20 µL) was added. The flask was allowed to rotate for 10 min at 80 °C in a water bath. After cooling to RT, the reaction mixture was quenched with aqueous NaHCO₃ (1 M, 1 mL) and extracted with dichloromethane (3 × 1.5 mL). The combined extracts were washed with aqueous NaHCO₃ (1 M, 1.5 mL) and water (1.5 mL), dried over Na₂SO₄, and concentrated under reduced pressure. The crude product (29 mg) was purified using PTLC (silica, cyclohexane/AcOEt 5:3), yielding 16 mg (39%) of H9, a light orange solid.

Compound H9: IR (ATR, v_max, cm⁻¹): 3267, 3075, 3001, 2971, 2848, 1750, 1637, 1595, 1540, 1480, 1239, 1239, 1139, 1025, 910, 873, 809; ¹H-NMR (CDCl₃) δ 7.62 (s, br 1H, NH), 7.18 (s, 1H, H-2'), 7.10 (d = 8 Hz, 1H, H-4), 7.07 (s, 2H, H-6, H-6'), 6.89 (d, J = 8 Hz, 1H, H-3), 6.06 (ddt, J = 16.9, 10.3, 6.6 Hz, 1H, H-2′′′), 5.97 (ddt, J = 17.9, 9.9, 6.9 Hz, 1H, H-2′′′), 5.03-5.15 (m, 4H, H-3′′′, H-3′), 3.77 (s, 3H, OCH₃), 3.50 (d, J = 5.9 Hz, 2H, H-1′′′), 3.35 (d, J = 6.6 Hz, 2H, H-1′′′), 2.22 (s, 3H, CO-CH₃); ¹³C-NMR (CDCl₃) δ 170.5 (CO), 154.7 (C-2), 146.0 (C-4′), 137.7 (C-2′′′), 136.8 (C-2′′′), 132.3 (C-5), 130.9 (C-6), 130.4 (C-5′), 130.2 (C-3′), 129.6 (C-1), 128.8 (C-2′), 128.2 (C-4), 125.2 (C-1′), 121.4 (C-6′), 115.7 (C-3′′′), 115.6 (C-3′′′), 111.4 (C-3), 55.8 (OCH₃), 39.4 (C-1′), 35.9 (C-1′′′), 23.7 (CO-CH₃); ESI⁺ calc'd for C₂₁H₂₃NO₃: [M]+ 337.168; found ESI-MS m/z (rel. int.): 338.08 [M + H]⁺ (100).

Bis(2-Allyloxyphenyl)-methane (B1a)

B1 (400 mg, 2.0 mmol) was O-allylated with alkylbromide (968 mg, 0.70 mL, 8.0 mmol) and K₂CO₃ (2.21 g, 16 mmol) in acetone (10 mL). The reaction mixture was stirred for 5 h with reflux, and a further 12 h at RT and filterated. The residue was concentrated with acetone (50 mL) and the combined organic solutions were evaporated under reduced pressure yielding B1a (559 mg, 73%).

Compound B1a: IR (ATR, v_max, cm⁻¹): 3025, 2920, 2905, 1595, 1584, 1491, 1450, 1421, 1248, 1116, 1103, 1022, 924, 751 cm⁻¹; ¹H-NMR (CDCl₃) δ 7.19 (td, J = 7.6, 1.5 Hz, 2H, H-4), 7.14 (dd, J = 7.5, 1.2 Hz, 2H, H-6), 6.90 (t, J = 7.5 Hz, 2H, H-5), 6.89 (d, 2H, J = 7.5 Hz, H-3), 6.02-6.13 (m, 2H, CH₂-CH₂=CH₂), 5.42 (dqnt, J = 17.2, 4.3 Hz, 2H, CH₂-CH₂=CH₂), 5.27 (dqnt, J = 10.5, 1.4 Hz, 2H, CH₂-CH₂=CH₂), 4.58 (dq, J = 5.0, 1.5 Hz, 2H, CH₂-CH₂=CH₂), 4.10 (s, 2H, Ar-CH₂=Ar); ¹³C-NMR (CDCl₃) δ 156.5 (C-2), 133.6 (CH=CH₂), 130.5 (C-6), 129.6 (C-1), 126.9 (C-4), 120.5 (C-5), 116.8 (CH=CH₂), 111.6 (C-3), 30.8 (O-CH₂), 29.8 (Ar-CH₂=Ar); EI⁺ calc'd for C₁₉H₂₀O₂: [M]+ 280.1463; found EI-MS m/z (rel. int.): 280.1465 [M]+ (100). Compound B1a has been mentioned in several patents; however, chemical data were not given therein.

2-Allyl-6-(3-allyl-2-hydroxybenzyl)-phenol (B2) and 4-Allyl-2-(3-allyl-2-hydroxybenzyl)-phenol (B3)

Claisen rearrangement of B1a (561 mg, 2 mmol) in N,N-diethylaniline (4 mL) following the procedure of Chattopadhyay et al. [21] resulted in B2 (410 mg; 73%) and B3 (89 mg; 15%) as white wax like solids.

Compound B2: IR (KBr, v_max, cm⁻¹): 3407 (br, OH), 3073, 3035, 2975, 2937, 1639, 1590, 1461, 1448, 1372, 1294, 1234, 1210, 1192, 1086, 999, 922, 912, 754 cm⁻¹; ¹H-NMR (CDCl₃) δ 7.20 (dd, J = 7.7, 1.5 Hz, 2H, H-6), 7.02 (d, J = 7.7 Hz, 2H, H-4), 6.88 (t, J = 7.7 Hz, 2H, H-5), 6.43 (s, br, 2H, OH), 6.06 (ddt, J = 16.8, 10.3, 6.2 Hz, 2H, CH₂-CH₂=CH₂), 5.18-5.24 (m, 4H, CH₂-CH₂=CH₂), 3.97 (s, 2H, Ar-CH₂=Ar), 3.45 (d, J = 6.6 Hz, 4H, CH₂-CH₂=CH₂); ¹³C-NMR (CDCl₃) δ 151.4 (C-2), 136.6 (CH₂=CH₂), 129.1 (C-6), 128.7 (C-4), 127.1 (C-1), 125.8 (C-3), 121.1 (C-5), 116.6 (CH₂-CH₂=CH₂), 35.4 (CH₂-CH₂=CH₂), 30.8
(Ar–CH₂–Ar); EI⁺ calculated for C₁₉H₂₀O₂: [M⁺] 280.1463; found EI-MS m/z (rel. int.): 280.1469 [M⁺] (58).

Compound B2 has been mentioned in several patents; however, chemical data were not given therein.

Compound B3: IR (KBr, νₓmax cm⁻¹): 3387 (OH), 3077, 2853, 1638, 1611, 1592, 1506, 1465, 1434, 1256, 1232, 1215, 1107, 996, 914, 759 cm⁻¹. H-NMR (CDCl₃) δ 7.17 (dd, J = 7.8, 1.5 Hz, 1H, H-6), 7.06 (d, J = 2.2 Hz, 1H, H-6'), 6.98 (dd, J = 7.3, 1.5 Hz, 1H, H-4), 6.91 (dd, J = 8.4, 2.2 Hz, 1H, H-4'), 6.84 (t, J = 7.5 Hz, 1H, H-5), 6.74 (d, J = 8.0 Hz, 1H, H-3'), 6.31 (s, vb, 2H, OH), 6.02 (ddt, J = 16.8, 10.3, 6.2 Hz, 1H, 2°-H), 5.92 (ddt, J = 16.9, 10.3, 6.6 Hz, 1H, H-2''), 5.19 (dq, J = 16.1, 1.7 Hz, 1H, H-3'''), 5.18 (dq, J ≈ 9, 1.5 Hz, 1H, H-3''''), 5.03 (dq, J ≈ 17, 1.8 Hz, 1H, H-3'''''), 5.04 (dq, J ≈ 9, 1.3 Hz, 1H, H-3''''), 3.89 (s, 2H, Ar–CH₂–Ar), 3.41 (d, J = 6.2 Hz, 2H, H-1'''), 13C-NMR (CDCl₃) δ 151.3 (C-2), 151.2 (C-2'), 137.8 (C-2'''), 136.5 (C-2''''), 132.8 (C-5'), 130.8 (C-6'), 129.1 (C-6), 128.8 (C-4), 128.0 (C-4'), 127.1 (C-1a), 126.6 (C-1), 125.6 (C-3), 121.2 (C-5), 116.9 (C-3'''), 116.0 (C-3''''), 115.4 (C-3'''''), 39.4 (C-1'''), 35.6 (C-1''''), 30.8 (Ar–CH₂–Ar); EI⁺ calculated for C₁₉H₂₀O₂: [M⁺] 280.1463; found EI-MS m/z (rel. int.): 280.1464 [M⁺] (100).

2,4'-Diallyloxy-diphenylmethane (C1a)

C1 (3.77 g, 18.8 mmol) was allylated with allyl bromide (8.97 g, 6.5 mL, 74.1 mmol) and K₂CO₃ (20.8 g, 0.15 mol) in acetone (100 mL) as described above yielding the diallyloxy-diphenylmethane (4.12 g, 78%).

Compound C1a: IR (ATR, νₓmax cm⁻¹): 3077, 3022, 2915, 2860, 1610, 1599, 1584, 1508, 1490, 1451, 1237, 1221, 1020, 996, 921, 749 cm⁻¹; 1H-NMR (CDCl₃) δ 7.22 (td, J ≈ 8, 1.3 Hz, 1H, H-4), 7.21 (d, J ≈ 8 Hz, 2H, H-2' and H-6'), 7.14 (d, J = 7.7 Hz, 1H, H-6), 6.94 (t, J = 7.3 Hz, 1H, H-5), 6.90 (d, 1H, J ≈ 8 Hz, H-3), 6.89 (d, 2H, J = 8.4 Hz, H-3' and H-5'), 6.03–6.17 (m, 2H, H-2' and H-2''), 5.45 (dq, J = 17.2, 1.5 Hz, 1H, H-3''''), 5.44 (dq, J = 17.3, 1.5 Hz, 1H, H-3'''''), 5.32 (dq, J = 10.5, 1.5 Hz, 1H, H-3''''), 5.31 (dq, J = 10.5, 1.5 Hz, 1H, H-3'''''), 4.58 (dt, J = 5.1, 1.5, 2H, H-1'''), 4.55 (dt, J = 5.1, 1.5, 2H, H-1''''), 4.02 (s, 2H, Ar–CH₂–Ar); 13C-NMR (CDCl₃) δ 156.7 (C-4'), 156.2 (C-2), 2 × 133.5 (2 × CH=CH₂), 133.3 (C-1'), 130.4 (C-1'), 130.2 (C-6), 129.8 (C-2' and C-6'), 127.2 (C-2-C), 120.6 (C-5), 117.4 (C-3'''), 116.9 (C-3'''''), 114.5 (C-3' and C-5'), 111.7 (C-3), 68.8 and 68.7 (2 × O–CH₂), 35.1 (Ar–CH₂–Ar); EI⁺ calculated for C₁₉H₂₀O₂: [M⁺] 280.1463; found EI-MS m/z (rel. int.): 280.1 [M⁺] (45), 133.1 [C₆H₄–O–allyl]⁺ (100).

2-Allyl-4-(3-allyl-2-hydroxybenzyl)-phenol (C2) and 2-Allyl-4-(5-allyl-2-hydroxybenzyl)-phenol (C3)

Claisen rearrangement of Chattopadhyay et al. [21] resulted in C2 (10.6 g; 73%) and C3 (1.2 g; 8.3%).

Compound C2: IR (ATR, νₓmax cm⁻¹): 3507 (br, OH), 3076, 3009, 2977, 2906, 1637, 1609, 1591, 1501, 1461, 1432, 1328, 1255, 1182, 996, 911, 751 cm⁻¹; 1H-NMR (CDCl₃) δ 6.95–7.06 (m, 4H, H-4-H-6, H-2', H-6'), 6.86 (t, J = 7.5 Hz, 1H, H-5), 6.74 (d, J = 7.7 Hz, 1H, H-5'), 5.94–6.09 (m, 2H, H-2''', H-2'''''), 5.12–5.20 (m, 4H, H-3''', H-3'''''), 4.99 (s, 2H, OH), 3.92 (s, 2H, Ar–CH₂–Ar), 3.41 (d, J = 6.2 Hz, 2H, H-1'''), 3.38 (d, J = 6.2 Hz, 2H, H-1'''''); 13C-NMR (CDCl₃) δ 152.6 (C-4'), 152.4 (C-2), 136.5 (C-2'''), 136.4 (C-2'''''), 132.1 (C-1'), 130.7 (C-2'), 129.1 (C-6), 128.6 (C-4), 128.0 (C-6'), 127.6 (C-1), 125.6 (C-3, C-5'), 116.4 (C-3'', C-3'''''), 116.0 (C-5'), 35.7 (Ar–CH₂–Ar), 35.3 (C-1'), 35.1' (C-1'''); EI⁺ calculated for C₁₀H₁₂O₂: [M⁺] 280.1463; found EI-MS m/z (rel. int.): 280.1465 [M⁺] (100).

General Procedure for the Methylation of Dihydroxy-Diphenylmethanes
The corresponding diol (1 eq) was dissolved in aqueous KOH (10%, 2.5 eq) and stirred for 10 min. MeSO₄ (1.2 eq) was added and the resulting mixture was stirred for 20 min at RT and for 1 h at 95 °C. After cooling to RT, the mixture was acidified with aqueous HCl (2M) and extracted with chloroform (3 ×). The organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was chromatographed over silica with cyclohexane/AcOEt = 5:1.

 Bis(3-allyl-2-methoxyphenyl)methane (B₄a) and 6-allyl-2-(3-allyl-2-methoxybenzyl)-phenol (B₄b)

 Methylation of 420 mg (1.5 mmol) B2 resulted in 39 mg of starting material, 40 mg B₄a (8.6%) and 249 mg B₄b (57%).

**Compound B₄b:** IR (ATR, \( \nu_{\text{max}} \), cm⁻¹): 3320 (br, OH), 3001, 2978, 2975, 2944, 2908, 1641, 1632, 1591, 1422, 1446, 1430, 1220, 1086, 998, 910, 780, 604 cm⁻¹; \(^1\)H-NMR (CDCl₃) \( \delta \) 7.09 (dd, \( 2H, J = 7.6 \) and 1.3 Hz, H-4), 7.00 (t, \( 2H, J = 7.5 \) Hz, H-5), 6.93 (dd, \( 2H, J = 7.4 \) and 1.3 Hz, H-6), 5.97–6.09 (m, \( 2H, -\text{CH}=\text{CH}_2 \)), 5.06–5.21 (m, \( 4H, -\text{CH}=\text{CH}_2 \)), 4.10 (s, \( 2H, -\text{Ar} \)), 3.72 (s, \( 6H, O\text{C}-\text{O} \)), 3.46 (d, \( 4H, J = 6.6 \) Hz, \( \text{CH}_2=\text{CH}=\text{CH}_2 \)); \(^{13}\)C-NMR (CDCl₃) \( \delta \) 154.4 (C-2), 137.3 (C-CH=CH₂), 134.0 (C-1), 132.9 (C-3), 128.9 (C-6), 128.5 (C-4), 124.1 (C-5), 115.8 (C-CH=CH₂), 34.0 (C-CH=CH₂), 29.6 (Ar-CH₂-Ar). EI calc'd for C₂₁H₂₄O₂: [M]+ 308.1776; found EI-MS m/z (rel. int.): 308.1776 [M]+ (100).

**Compound C₂:** Methylation of 2.10 g (7.5 mmol) C₂ resulted in 143 mg of starting material, 318 mg C₄a (14%), 665 mg C₄b (30%) and 442 mg C₄c (20%).

**Compound C₄b:** IR (ATR, \( \nu_{\text{max}} \), cm⁻¹): 3001, 2977, 2939, 2833, 1638, 1500, 1463, 1429, 1248, 1125, 1080, 1033, 1010, 910, 768 cm⁻¹; \(^1\)H-NMR (CDCl₃) \( \delta \) 7.07 (dd, \( 2J = 7.3 \), 1.5 Hz, H-4), 6.98–7.02 (m, \( 3H, H=2', H-5 \) and H-6'), 6.96 (dd, \( 2J = 7.6 \), 1.3 Hz, H-1, H-6), 6.78 (d, \( 2J = 8.4 \) Hz, H-1, H-5'), 5.92–6.07 (m, \( 2H, H-2'' \) and H-2'''), 5.06–5.13 (m, \( 2H, H-3'' \)), 4.99–5.06 (m, \( 2H, H-3''' \)), 3.96 (s, \( 2H, -\text{Ar} \)), 3.80 (s, \( 3H, C_4'\text{-OCH}_3 \)), 3.68 (s, \( 3H, C_2\text{-OCH}_3 \)), 3.46 (d, \( 2J = 6.3 \) Hz, H-1'''), 3.36 (d, \( 2J = 6.6 \) Hz, H-2H'''); \(^{13}\)C-NMR (CDCl₃) \( \delta \) 156.3 (C-2), 155.6 (C-2''), 137.3 (C-2'''), 137.1 (C-2''''), 134.7 (C-1), 133.0 (C-3), 132.8 (C-1'), 130.2 (C-2''), 129.0 (C-6), 128.5 (C-4), 128.4 (C-3'), 127.5 (C-6'), 120.5 (C-5), 115.8 (C-3'''), 115.3 (C-3''''), 110.3 (C-5'), 61.2 (C₂-OCH₃), 55.5 (C₄′-OCH₃), 34.9 (Ar-CH₂-Ar), 33.4 (C-3'''''), 33.0 (C-1'''''); MS (EI) m/z (%): calculated for C₂₆H₂₄O₃ [M]+ 308.178; found: EI-MS m/z (rel. int.): 308.4 [M]+ (100).

**Compound C₄c:** IR (ATR, \( \nu_{\text{max}} \), cm⁻¹): 3526 (br, OH), 3003, 2976, 2905, 2834, 1637, 1608, 1592, 1499, 1461, 1247, 1182, 1032, 996, 910, 752 cm⁻¹; \(^1\)H-NMR (CDCl₃) \( \delta \) 6.97–7.02 (m, \( 4H, H-4 \), H-6, H-2'' and H-6''), 6.82 (t, \( 2J = 7.5 \) Hz, H-1, H-5), 6.76 (d, \( 2J = 8.8 \) Hz, H-1, H-5'), 5.90–6.05 (m, \( 2H, H-2'' \) and H-2''''), 5.11–5.17 (m, \( 2H, H-3'' ''), 4.98–5.05 (m, \( 2H, H-3'''', 4.94 (s, \( 1H, OH \)), 3.91 (s, \( 2H, -\text{Ar} \)), 3.38 (d, \( 2J = 6.2 \) Hz, H-1'''), 3.34 (d, \( 2J = 6.5 \) Hz, H-2H'''); \(^{13}\)C-NMR (CDCl₃) \( \delta \) 152.9 (C-4'), 152.4 (C-2), 136.9 (C-2'''), 136.5 (C-2'''), 131.4 (C-1'''), 130.2 (C-2'), 129.1 (C-6'), 128.8 (C-3'), 128. 6 (C-4), 127.6 (C-1), 127.2 (C-6), 125.5 (C-3), 120.5 (C-5), 116.4 (C-3'''), 115.3 (C-3'''''), 55.4 (OCH₃), 35.8 (Ar-CH₂-Ar), 35.3 (C-1'''), 34.3 (C-1'''''); MS (EI) m/z (%): calculated for C₂₆H₂₂O₃ [M]+ 294.162; found: EI-MS m/z (rel. int.): 294.4 [M]+ (80), 253.2 (65).
2H, H-2′′ and H-2′′′), 5.06–5.20 (m, 4H, H-3′′ and H-3′′′), 4.95 (s, 1H, OH), 3.96 (s, 2H, Ar–CH2–Ar), 3.68 (s, 3H, OCH3), 3.46 (d, J = 6.6 Hz, 2H, H-1′′′), 3.38 (d, J = 6.5 Hz, 2H, H-1′′′), 13C-NMR (CDCl3) δ 156.3 (C-2), 152.3 (C-4′), 137.3 (C-2′′), 136.5 (C-2′′′), 134.6 (C-1), 133.3 (C-1′), 133.0 (C-3), 130.1 (C-2′), 129.0 (C-6), 128.6 (C-4), 128.2 (C-6′), 125.1 (C-3′), 124.1 (C-5), 116.3 (C-3′′), 115.8 (C-3′′′), 115.7 (C-5′), 61.2 (OCH3), 35.2 (C-1′′′), 34.9 (Ar–CH2–Ar), 33.9 (C-1′), MS (EI) m/z (%): calculated for C20H22O2: [M]+ 294.162; found: EI-MS [M]+ (75), 253.2 (40).

3.2. Biological Assays

**Cell line:** All screening was done in a line of human embryonic kidney cells stably expressing the human norepinephrine transporter and the vesicular monoamine transporter 2 (HEK-hNET-hVMAT2-mCherry). Human VMAT2 expression, in addition to hNET, more fully recapitulates a neuronal phenotype in cell culture. Cells were imaged and fully characterized for functionality (Figure 1). For imaging, cells were fixed in 4% paraformaldehyde and protein expression of NET determined by immunolabelling (primary antibody: Novus, anti-norepinephrine transporter, 1:1000; secondary antibody: Thermo Fisher, Alexafluor goat anti-rabbit-488, 1:5000) followed by confocal imaging (Nikon A1R, Nikon Instruments, Melville, NY, USA). **Screening:** Synthesized compounds were tested for interaction with NET via a three-step process. First, all compounds were tested using a commercially available fluorescent assay (neurotransmitter transport uptake kit, Molecular Devices, San Jose, CA, USA) for the assessment of plasmalemmal monoamine transport ability [23,24]. Cells were plated in poly-d-lysine (PDL)-coated 96-well plates (Corning Inc., Corning, NY, USA) to 100% confluence. The following day, cell media (DMEM, 10% fetal bovine serum, 1% penicillin/streptomycin) was removed, and experimental media (Hank’s balanced salt solution, 1:1000; secondary antibody: Thermo Fisher, Alexafluor goat anti-rabbit-488, 1:5000) followed by fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit antibody (Thermo Fisher, 1:1000) was added. Following a 30-min incubation at 37 °C, dye was added to all wells, with or without compounds (3 nM–100 µM final concentration) or selective NET inhibitor desipramine (3 nM–10 µM final concentration, control). Plates were incubated for 1 h, then read on a fluorescent plate reader (Thermo Fisher). Experiments were conducted in triplicate. Second, the most potent modulators of transport activity (C4a, H8, H11, H16, H20 and M6) were further assessed for radiolabeled dopamine uptake in the same cell line, as dopamine is a substrate of NET [25,26]. Cells were plated to confluence in 48-well PDL-coated plates the day prior to the experiment. For experiments, media was removed, cells were rinsed with phosphate buffered saline (PBS), and incubated with or without compounds or desipramine (10 nM to 10 µM, non-specific uptake measured by addition of 100 µM desipramine) for ten minutes at 37 °C. Dopamine (1 µM total concentration with 200 nM 3H-dopamine tracer) was added and uptake proceeded for 10 min at 37 °C. Cells were then rinsed three times with PBS, lysed with 0.1 N NaOH, and measured via liquid scintillation counting (Beckman Coulter, Brea, CA, USA). Finally, each selected compound was visualized with high-content imaging using the Array Scan VTI HCS (Cellomics). Cells were seeded to 80% confluence in PDL-coated, glass-bottom 96-well plates. Media was removed and DMEM without phenol red with or without compounds or desipramine (10 nM to 10 µM) was added. Following a one-hour incubation, cells were imaged. Forty-nine contiguous fields per well were taken and total fluorescence in the green channel was reported. No compound demonstrated potent activity at NET (IC50 > 100 µM), as compared with the selective NET inhibitor, desipramine, which inhibited fluorescent (plate reader: IC50 = 125.3 nM; imaging: IC50 = 65.7 nM, Figures 1.1 and 3) and radioactive uptake (IC50 = 52.1 nM, Figure 1.2). Dose-Response curves (measured as fluorescence) for tested compounds can be found in “Supplementary Materials”.

4. Conclusions

Altogether, we tested a series of 52 biphenyl neolignans and derivatives (including diphenyl-methane analogs) found in biological preparations that are used to treat anxiety and insomnia in Eastern medicine, for pharmacological efficacy at the NET. No tested compound potently inhibited uptake via NET, suggesting acutely that these compounds may work exclusively through GABA_A receptor modulation. It is also possible that these compounds still modulate the noradrenergic system;
long-term treatment with the compounds could change tissue expression of receptors or affect the tissue level of norepinephrine, potentially by modulating enzymes that produce and metabolize the neurotransmitter. Future experiments are needed to determine if chronic administration of drugs may change noradrenergic signaling. Within the context of these experiments, however, we see no evidence for acute modulation of NET activity by biphenyl neolignans or derivatives. It is also of note that serotonergic signaling also plays a major role in anxiety and depression. Though beyond the scope of this work, investigation of honokiol derivatives at serotonin receptors may provide further information as to how these compounds exert their anxiolytic effect.

**Supplementary Materials:** Proton NMR spectra of the new compounds and dose-response curves of the tested compounds are available in “Supplementary Materials”.

**Author Contributions:** W.S. concept, funding acquisition, HPLC separation, GC-MS measurements and purity control of compounds, analyzing data, writing the manuscript. K.S. and G.W.M. design and carryout of pharmacological investigation, data analysis, writing and correcting the manuscript. M.B. design and performing of the syntheses. A.H. Design of chemical syntheses, performing synthetic research, performing NMR spectroscopic experiments and data analysis, writing of the manuscript.

**Funding:** Parts of this work were supported by the Austrian Science Fund (FWF) under a grant “Synthesis of new GABA<sub>A</sub> receptor modulators” (P21241).

**Acknowledgments:** We are indebted to Andreas Leitner for recording IR spectra. We thank R. Bauer and F. Bucar (Institute of Pharmaceutical Sciences Graz) for the use of preparative HPLC, ESI-MS and GC-MS facilities, respectively.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**


Sample Availability: Samples of the compounds are available from WS and AH. The availability can only be guaranteed for compounds that remain stable under storage conditions.